Onward Clinical Trial for Geographic Atrophy (GA)

If you or someone you know has been diagnosed with an advanced form of dry age-related macular degeneration (AMD) called geographic atrophy (GA), you may be interested in learning about a new clinical research study.

Doctors and researchers want to see if an investigational medicine called danicopan [da-NIH-co-pan] can safely help slow or stop this condition from getting worse. Danicopan has been tested in other clinical studies and found to be well tolerated and safe. Danicopan is an oral tablet taken once or twice daily by mouth.

The main study lasts up to 2 years and 3 months. The majority of the visits will take place at the study clinic. Participants may have some home visits if they wish to do so and if the study clinic allows them.

The study has 3 parts:

  • Screening: Participants will have tests and health checks to see if the study is right for them.
  • Treatment (Year 1 and Year 2): Participants will take danicopan or placebo during the first year. Participants will receive danicopan in the second year.
  • Dose Decrease and Follow-up: Study medicine dose will be slowly decreased. Then there will be one final visit for a health check after participants have stopped taking the study medicine.

As part of the study, participants will have physical exams, eye exams, and lab tests so that the study doctors and researchers can evaluate the safety and efficacy of the study drug.

Find out more at